Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke
Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2012-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1422-0067/13/7/8670 |
| _version_ | 1811276905813377024 |
|---|---|
| author | Karin Weissenborn Ralf Lichtinghagen Hans Worthmann Reinhard Dengler Wolfgang G. Eisert Andreas Schwartz Helmut Schumacher |
| author_facet | Karin Weissenborn Ralf Lichtinghagen Hans Worthmann Reinhard Dengler Wolfgang G. Eisert Andreas Schwartz Helmut Schumacher |
| author_sort | Karin Weissenborn |
| collection | DOAJ |
| description | Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy (<em>p</em> > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217–973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (<em>p</em> = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP. |
| first_indexed | 2024-04-13T00:06:11Z |
| format | Article |
| id | doaj.art-c14acc43006a456eb9da95f8a339b37e |
| institution | Directory Open Access Journal |
| issn | 1422-0067 |
| language | English |
| last_indexed | 2024-04-13T00:06:11Z |
| publishDate | 2012-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-c14acc43006a456eb9da95f8a339b37e2022-12-22T03:11:14ZengMDPI AGInternational Journal of Molecular Sciences1422-00672012-07-011378670867810.3390/ijms13078670Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic StrokeKarin WeissenbornRalf LichtinghagenHans WorthmannReinhard DenglerWolfgang G. EisertAndreas SchwartzHelmut SchumacherInflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy (<em>p</em> > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217–973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (<em>p</em> = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP.http://www.mdpi.com/1422-0067/13/7/8670ischemic strokemonocyte chemoattractant protein-1 (MCP-1)antithrombotic therapyneuroprotectiondipyridamoleacetylsalicylic acid (ASA) |
| spellingShingle | Karin Weissenborn Ralf Lichtinghagen Hans Worthmann Reinhard Dengler Wolfgang G. Eisert Andreas Schwartz Helmut Schumacher Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke International Journal of Molecular Sciences ischemic stroke monocyte chemoattractant protein-1 (MCP-1) antithrombotic therapy neuroprotection dipyridamole acetylsalicylic acid (ASA) |
| title | Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke |
| title_full | Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke |
| title_fullStr | Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke |
| title_full_unstemmed | Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke |
| title_short | Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke |
| title_sort | monocyte chemotactic protein 1 as a potential biomarker for early anti thrombotic therapy after ischemic stroke |
| topic | ischemic stroke monocyte chemoattractant protein-1 (MCP-1) antithrombotic therapy neuroprotection dipyridamole acetylsalicylic acid (ASA) |
| url | http://www.mdpi.com/1422-0067/13/7/8670 |
| work_keys_str_mv | AT karinweissenborn monocytechemotacticprotein1asapotentialbiomarkerforearlyantithrombotictherapyafterischemicstroke AT ralflichtinghagen monocytechemotacticprotein1asapotentialbiomarkerforearlyantithrombotictherapyafterischemicstroke AT hansworthmann monocytechemotacticprotein1asapotentialbiomarkerforearlyantithrombotictherapyafterischemicstroke AT reinharddengler monocytechemotacticprotein1asapotentialbiomarkerforearlyantithrombotictherapyafterischemicstroke AT wolfganggeisert monocytechemotacticprotein1asapotentialbiomarkerforearlyantithrombotictherapyafterischemicstroke AT andreasschwartz monocytechemotacticprotein1asapotentialbiomarkerforearlyantithrombotictherapyafterischemicstroke AT helmutschumacher monocytechemotacticprotein1asapotentialbiomarkerforearlyantithrombotictherapyafterischemicstroke |